HK1064040A - Breath protection microcapsules - Google Patents

Description

Breath protection microcapsules

Technical Field

The present invention relates to oral compositions in the form of microcapsules for reducing oral bacteria and providing long lasting oral protection.

Background

The use of oral control compositions such as oral mints, mouthwashes, chewing gums and the like is common in developed countries throughout the world. Another form that has been used is microcapsules containing a flavoring agent or other oral protective agent. These implementations are accepted not only because they are useful away from the place where the mouthwash is expectorated, but also because they can be swallowed when the user no longer needs them to function or no longer wants the microcapsules to be present in the mouth.

Although microcapsules have been used, there is still a need for improvements in such products.

Thymol, also known as an essential oil, is a well-known antibacterial agent used in various mouthwash formulations due to its antimicrobial activity. In particular, thymol can be applied in oral hygiene compositions such as mouthwashes in an amount sufficient to provide the desired beneficial therapeutic effect. LISTERINE^TMAre well known mouthwashes which have been used by countless people for over a hundred years and have proven effective in killing microorganisms in the oral cavity which are responsible for plaque, gingivitis and bad breath. Thymol and other essential oils such as methyl salicylate, menthol and eucalyptol are antibacterial gargle such as LISTERINE^TMAn active ingredient (e.g., an antimicrobial agent) of (a). These oils have proved to be very effectiveSmall amounts are present but their effectiveness can be achieved. Without wishing to be bound by any particular theory, it is presently believed that antibacterial mouthwashes such as LISTERINE^TMThe efficacy and taste of (a) can be attributed to the dissolution and delivery kinetics of these four active ingredients.

Unfortunately, thymol, as well as the above essential oils, while providing beneficial therapeutic effects, also provide the consumer with a taste sensation that can be described as unpleasant, irritating, or medicinal in terms of taste. What is desired in the art would be a composition containing thymol wherein the unpleasant, irritating, or medicinal taste of the thymol has been effectively masked. Such a taste masked composition would provide a pleasant acceptable taste to the consumer.

The present inventors have found that by incorporating chlorodeoxysucrose derivatives, the unpleasant taste of thymol can be masked leaving the consumer with a pleasant taste.

It is therefore an aspect of the present invention to provide for improved microcapsules.

It is another aspect of the present invention to provide microcapsules with improved respiratory control and antimicrobial activity.

It is yet another aspect of the present invention to provide improved methods of oral control and reduction of oral bacteria.

It is another aspect of the present invention to provide improved oral control and antimicrobial microcapsules comprising at least one essential oil in combination with a chlorodeoxysucrose derivative.

These and other aspects of the invention will become more apparent from the detailed description below.

Summary of The Invention

The present invention relates in one of its aspects to microcapsules comprising a shell material and a core material, wherein the microcapsules contain at least one essential oil in combination with a chlorodeoxysucrose derivative, preferably a mixture of thymol, methyl salicylate, eucalyptol and menthol (menthol). Preferably, the microcapsules of the present invention are of the fast dissolving type.

All percentages and ratios used herein are by weight unless otherwise indicated. In addition, all measurements were performed at 25 ℃ unless otherwise indicated.

The compositions of the present invention may comprise, consist essentially of, or consist of the essential and optional components and ingredients described herein. As used herein, "consisting essentially of means that the composition or ingredient may include additional components, provided that the additional components do not materially alter the basic and novel characteristics of the claimed compositions or methods.

The term "rapidly (or rapidly) dissolving" as used herein means that the microcapsules dissolve in less than about 60 seconds, preferably less than about 30 seconds, more preferably less than about 15 seconds after being placed in the oral cavity.

Detailed Description

Essential and optional ingredients of the capsules of the invention are described in the following paragraphs.

Capsule shell material

The capsule shells of the present invention may be produced using conventional capsule preparation techniques. The shell material of the microcapsules of the present invention may be any material suitable for ingestion and retention in the oral cavity. Suitable materials include gelatin, polyvinyl alcohol, waxes, gums, sucrose esters, pullulan, and candy (candy) type materials used for cough drops and mints. For gelatin and gelatin-based capsules, for a review see Remington's Pharmaceutical sciences, 16 th edition, MackPublishing Company, Pa. (1980), pp 1245 and 1576-1582. Other materials and capsule preparation techniques can be found in U.S. Pat. nos. 2,800,458; 3,159,585, respectively; 3,533,958, respectively; 3,697,437, respectively; 3,888,689, respectively; 3,996,156, respectively; 3,965,033, respectively; 4,010,038 and 4,016,098, each of which is incorporated by reference herein in its entirety.

Shell materials are used to form a wide variety of shapes such as spheres, ovals, disks, loose squares (cylinders), and cylindrical shapes. The thickness of the shell is preferably from about 30 μm to about 2mm, more preferably from about 70 μm to about 110 μm. If the microcapsules are spherical, the particles generally have a diameter of from about 2mm to about 9mm, preferably from about 3mm to about 7 mm.

Core material

Essential oil

The microcapsules of the present invention contain a core material comprising a mixture of essential oils. Preferably, the core material is present in a single phase composition. Suitable essential oils include, but are not limited to, anethole, anise oil, bay oil, bergamot oil, bitter almond oil, bubble-gum flavoring (bubble-flavoring), cedar leaf oil, cinnamaldehyde, cinnamon oil, clove oil, eucalyptol, eucalyptus oil, eugenol, lavender oil, menthol, peppermint oil, sassafras oil, spearmint oil, terpeneless spearmint oil, thyme oil (thyme oil), thymol, wintergreen oil (methyl salicylate), and mixtures thereof. Preferred essential oils include thymol, methyl salicylate, eucalyptol, menthol and mixtures thereof.

Thymol, (CH)₃)₂CHC₆H₃(CH₃) OH (isopropyl-m-cresol) is only slightly soluble in water, but soluble in alcohol. Salicylic acid methyl ester (C)₆H₄OHCOOCH₃) Also known as wintergreen oil, provides a flavoring to the mouthwash while also having an antimicrobial function. Cineole (C)₁₀H₁₈O; eucalyptol) is a terpene ether that provides a cool, pungent taste. Menthol (CH)₃C₆H₉(C₃H₇) OH; hexahydrothymol) is also highly alcohol soluble, very volatile, and provides a cooling, tingling sensation in addition to having antimicrobial properties.

In the microcapsules of the present invention, the essential oil is used in an amount effective to provide antimicrobial activity in the oral cavity. Generally, the total amount of essential oil present in the microcapsules may be from about 1% to about 50% w/w, optionally from about 5.0% to about 45%, or optionally from about 10% to about 30%, or optionally from about 15% to about 25%.

Thymol is preferably employed in the microcapsules of the present invention in an amount of from about 0.001% to about 5% w/w, and most preferably from about 0.01% to about 3% w/w. Eucalyptol is preferably used in an amount of about 0.001% to about 5% w/w, and most preferably about 0.01% to about 3% w/w. Menthol is preferably used in an amount of about 0.1% to about 25% w/w, most preferably about 1% to about 20% w/w, and, optionally, about 3% to about 15% w/w. Methyl salicylate is preferably used in an amount of about 0.001% to about 5% w/w, and most preferably about 0.01% to about 3% w/w.

The components being present in the shell or core material

Chlorodioxysucrose derivatives

The microcapsule of the present invention further comprises a chlorodeoxysucrose derivative. The chlorodeoxysucrose derivative has a general formula (I)

Wherein R is¹Represents a hydroxyl group or a chlorine atom; r²And R³Respectively represents a hydroxyl group and a hydrogen atom, a chlorine atom and a hydrogen atom, or a hydrogen atom and a chlorine atom, wherein the 4-position is in the D-configuration; r⁴Represents a hydroxyl group; or, if R is¹、R²、R³And R⁵In which at least two represent chlorine atoms, then R⁴Represents a hydroxyl group or a chlorine atom; and R is⁵Represents a hydroxyl group or a chlorine atom; with the following conditions: r¹、R²、R³And R⁵At least one of them represents a chlorine atom.

It is desirable to replace at least a portion of the sucrose in the diet with these compounds and thus act as non-cariogenic materials.

Specific examples of compounds of formula (I) above are as follows (the system name is given first, followed by the trivial name given with "galactosucrose" in the presence of the converted 4-chloro substituent):

1, 1 '-chloro-1' -deoxy sucrose

4-chloro-4-deoxy-alpha-D-galactopyranosyl-beta-D-fructofuranoside [ i.e. 4-chloro-4-deoxy galactosucrose ]

4-chloro-4-deoxy-alpha-D-galactopyranosyl-1-chloro-1-deoxy-beta-D-fructofuranoside [ i.e. 4,1 '-dichloro-4, 1-4, 1' -dideoxy galactosucrose ]

4.1 ', 6' -dichloro-1 ', 6' -dideoxy sucrose

4-chloro-4-deoxy-alpha-D-galactopyranosyl-1, 6-dichloro-1, 6-dideoxy-beta-D-fructofuranoside [ i.e., 4,1 ', 6' -trichloro-4, 1 ', 6' -trideoxygalactosucrose ] also known as Sucralose (McNeil Specialty Products Company, Skillman, N.J.)

6.4, 6-dichloro-4, 6-dideoxy-alpha-D-galactopyranosyl-6-chloro-6-deoxy-beta-D-fructofuranoside [ i.e.4, 6, 6 '-trichloro-4, 6, 6' -trideoxygalactosucrose ]

7.6, 1 ', 6-trichloro-6, 1 ', 6 ' -trideoxy sucrose

4, 6-dichloro-4, 6-dideoxy-alpha-D-galactopyranosyl-1, 6-dichloro-1, 6-dideoxy-beta-D-fructofuranoside [ i.e. 4,6, 1 ', 6' -tetrachloro-4, 6,1 ', 6' -tetradeoxygalactosucrose ]

4,6, 1 ', 6' -tetrachloro-4, 6,1 ', 6' -tetradeoxysucrose.

In general chlorodeoxysucrose derivatives of sucrose are known. They can be obtained by reacting suitably protected sucrose with a chlorinating agent which introduces a chlorine atom at the desired position. Such reagents may replace the free hydroxyl group with a chlorine atom or may react with the esterified hydroxyl group to introduce chlorine. The positions to be protected can be esterified or protected with acetal or ether groups which are easily removed after chlorination. Typical reagents include sulfuryl chloride (sulphenyl chloride), which is used to form a chlorosulfate ester, which is treated with chloride ions to form the chlorodeoxysucrose derivative. A more detailed description of suitable methods of preparation can be found, for example, in U.S. patent nos. 4,343,934 and 4,435,440, both of which are incorporated herein by reference in their entirety. Additional chlorodeoxysucrose derivatives can be found in U.S. patent 4,389,394, which is incorporated herein by reference in its entirety. Mixtures of the above chlorodeoxysucrose may also be used.

The chlorodeoxysucrose derivatives are preferably present in the microcapsules of the present invention at a concentration of from about 0.001% to about 10%, more preferably from about 0.01% to about 5%, most preferably from about 0.1% to about 3%.

Optional Components

Additional substances suitable for use in capsule cores

Optionally and preferably used in the microcapsules of the present invention are suitable diluents. Suitable diluents can be found in U.S. patent 4,935,243, which is incorporated herein by reference in its entirety. Preferred are oils, such as corn oil, olive oil, rapeseed oil, sesame oil, peanut oil, sunflower oil, safflower oil, vegetable oil or mineral oil. Other preferred materials include triglycerides, such as capric/caprylic triglycerides (e.g., Neobee M5[ Stepan Chemical-Northfield, Illinois ] and Captex 300[ Karlsham Lipid Specialties-Columbus Ohio ]; succinylated monoglycerides of distilled fatty acids, such as the Myverol product series (Eastman Chemicals Co.); stearates (Lipo) and polyethylene glycols such as PEG 400. these materials are further described in U.S. Pat. Nos. 6,117,835; 6,096,338; 6,083,430; and 6,045,835, each of which is incorporated herein by reference in its entirety.

Also optionally used in the microcapsules of the present invention are humectants. The humectant functions to retain water on/in the oral surfaces. Examples of suitable humectants include polyols selected from the group consisting of: ethylene glycol, propylene glycol, dipropylene glycol, butylene glycol, hexylene glycol, polyethylene glycol, glycerin sorbitol (glycerol sorbitol), panthenol, urea, alkoxylated glucose derivatives such as glucam (rtm) E-20, hexanetriol, glucose ethers, sodium hyaluronate, soluble chitosan, and mixtures thereof. Glycerol and/or sorbitol are preferred.

Sorbitol for use in the present invention is sold by Company Roquette under the trade name Neosorb P60W or Neosorb P-60. The glycerol used in the present invention is preferably "glycerol, USP, 99.5%", most preferably those sold by Dow Chemical, Inc., Emery Industries, Inc. (under the trade name "Superol 99.5%") and Procter & Gamble.

The humectant is preferably present in the microcapsules of the present invention at a concentration of from about 0.01% to about 12%, preferably from about 0.5% to about 8%, more preferably from about 1% to about 4%.

The core of the microcapsules of the present invention may also contain any of a variety of additional materials to provide additional breath freshening effects and/or sensory sensations. Such materials may include quaternary ammonium salts such as pyridinium salts (e.g., cetylpyridinium chloride), domiphen bromide, other cationic materials such as chlorhexidine salts, zinc salts, and copper salts. Other materials such as phenolic resins (phenolics), chlorhexidine, triclosan, peroxides, povidone iodine, chlorine dioxide (chlororine), neem, wild indigo, berberis, green tea, calendula, fennel, goldthread (golden seal), shrub (chaparrel), chamomile, propolis, thyme, calendula, and additional non-cationic water-insoluble materials may also be used. Such materials are disclosed in U.S. patent 5,043,154, aug.27, 1991, which is incorporated herein by reference in its entirety. Mixtures of the above oral control antimicrobial agents may also be used. These oral control/antimicrobial agents are used in amounts of about 0.001% to about 2%, preferably about 0.005% to about 1%, based on the total core content.

Anti-malodour agents for use in the present invention used at levels which produce a satisfactory malodour masking effect include, but are not limited to, zinc salts, copper salts, chlorophyllin (chlorophyllin), alpha-ionone, geraniol, parsley seed and mixtures thereof.

Fluorine-providing compounds may also be present in the microcapsules of the present invention. These compounds may be slightly or completely soluble in water and are characterized by the ability to release fluoride or fluoride-containing ions in water. Typical fluorine donating compounds are inorganic fluoride salts such as amine fluorides, alkali metal, alkaline earth metal and heavy metal salts such as sodium fluoride, potassium fluoride, ammonium fluoride, cuprous fluoride, zinc fluoride, tin fluoride, stannous fluoride, barium fluoride, sodium fluorozirconate, sodium monofluorophosphate, aluminum mono-and difluorophosphate, sodium calcium fluoropyrophosphate, acidified monofluorophosphate and mixtures thereof.

Alkali metals, tin fluorides and monofluorophosphates such as sodium fluoride and stannous fluoride, sodium monofluorophosphate and mixtures thereof are preferred.

In the microcapsules of the present invention, the fluorine-providing compound is generally present in an amount sufficient to release up to about 0.15%, preferably from about 0.0005% to about 0.1%, most preferably from about 0.001% to about 0.05% fluorine by weight of the formulation.

In addition, in addition to the chlorodeoxysucrose derivatives described above, a wide variety of sweeteners may be included in the core or shell of the microcapsules of the present invention. Suitable sweeteners may be selected from the following non-limiting examples: sugars such as sucrose, glucose (corn syrup), glucose, invert sugar, fructose and mixtures thereof, saccharin and its various salts such as sodium or calcium salts; cyclohexane sulfamic acid and its various salts such as sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; stevia rebaudiana (stevioside); glycyrrhizin, dipotassium glycyrrhizinate, phenylalanine 1-methyl ester (aspartame); chloro derivatives of sucrose; dihydroflavanol; hydroxyguaiacol ester; l-aminodicarboxylic acid gem-diamines; l-aminodicarboxylic acid aminoalkenoate amides; and sugar alcohols such as sorbitol, sorbitol syrup, mannitol, xylitol, and the like. Also useful as additional sweeteners are non-fermentable sugar substitutes (hydrogenated starch hydrolysates), which are described in U.S. patent 26,959. Synthetic sweeteners 3, 6-dihydro-6-methyl-1-1, 2, 3-oxathiazin-4-one (oxathiazin-4-one) -2, 2-dioxide, in particular potassium (acesulfame-k), L- α -aspartyl-N- (2, 2, 4, 4-tetramethyl-3-thietanyl) -D-alaninamide hydrate (commercial products of alitan, Pfizer, New York, n.y.); and thaumatin (Talin).

These sweeteners are used in amounts of about 0.1% to about 10%, preferably about 0.35% to about 3% by weight of the total capsule weight. For a more detailed description of additional and preferred sweetness and taste/flavor modifying materials, reference may be made to U.S. patent nos. 6,121,315 and 5,284,659, both of which are incorporated herein by reference in their entirety. Mixtures of any of the additional disclosed sweeteners can also be used.

Particularly preferred for use in the present invention in combination with chlorodeoxysucrose derivatives is acesulfame. Acesulfame is a synthetic sweetener 3, 6-dihydro-6-methyl-1-1, 2, 3-oxathiazin-4-one-2, 2-dioxide and is typically incorporated as acesulfame K (Sunnett brand sweetener available from Hoechst Celanes, Portsmouth, Va.) into the microcapsules of the present invention. The chlorodeoxysucrose derivative and acesulfame are preferably combined in a ratio of from about 1: 1 to about 9: 1, more preferably from about 2: 1 to about 7: 3.

Vitamins such as vitamin a (retinol and carotene derivatives); vitamin B (thiamine, riboflavin, niacin, pantothenic acid, biotin, vitamin B12, pyridoxine, folic acid, inositol); vitamin C (ascorbic acid); vitamin D (vitamin D2, vitamin D3, ergosterol); vitamin E (tocopherol); vitamin K (vitamin K1, menadione, tuberculin naphthoquinone) as well as other and more specific antioxidants may also be incorporated into the microcapsules of the present invention. Suitable and preferred vitamins and antioxidants can be found in U.S. Pat. No. 6,238,678, which is incorporated herein by reference in its entirety.

Microcapsules of the present invention may also contain one or more sensory or sensate active agents that act as a signal of heat or cooling.

When used in the present invention, a sensory or perceptual active agent may be present in an amount of from about 0.01% to about 10%, typically from about 0.1% to about 5%, preferably from about 0.2% to about 1%. The amount is selected to provide a basis that is perceptible to the consumer and can be adjusted as desired. Suitable sensory or perceptual actives include mannitol, inositol, physcool , menthol, eucalyptus components, 3-I-menthoxy (menthoxy) propane-1, 2-diol, N-substituted-p-menthane-3-carboxamide, and acyclic carboxamides.

3-I-menthoxypropane-1, 2-diol is described in detail in U.S. Pat. No. 4,459,425 to Amano et al, 1984, 7/10, which is incorporated herein by reference in its entirety. Such volatile fragrances are commercially available and are sold by Takasago Perfumery co., ltd., Tokyo, japan.

N-substituted-p-menthane-3-carboxamides are described in detail in U.S. Pat. No. 4,136,163 to Watson et al, 1979, 23, which is incorporated herein by reference in its entirety. The most preferred volatile fragrance of this type is N-ethyl-p-menthane-3-carboxamide, which is commercially available as WS-3 from Wilkinson Sword Limited.

Acyclic carboxamides that can be used are described in detail in U.S. Pat. No. 4,230,688 to Rowsell et al, 10/28 1980, which is incorporated herein by reference in its entirety. The most preferred such acyclic aromatic agent is N, 2, 3-trimethyl-2-isopropyl butanamide, which is commercially available as WS-23 from Wilkinson Sword Limited.

Suitable warming sensory or perceptual actives include anhydrous PEG, vanillyl alcohol n-butyl ether (TK-1000, supplied by Takasago Perfumery co., ltd., Tokyo, Japan), vanillyl alcohol n-propyl ether, vanillyl alcohol isopropyl ether, vanillyl alcohol isobutyl ether, vanillyl alcohol n-pentyl ether, vanillyl alcohol isoamyl ether, vanillyl alcohol n-hexyl ether, vanillyl alcohol methyl ether, vanillyl alcohol ethyl ether, gingerol, zingerone, capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, ethanol, isopropanol, isoamyl alcohol, benzyl alcohol, and mixtures thereof.

Mixtures of any of the above sensory or perceptual active agents may also be used.

The microcapsules of the invention may also contain sialagogues or agents that stimulate salivation. Such active agents include, but are not limited to, ascorbic acid, fumaric acid, citric acid, tartaric acid, malic acid, gluconic acid, pilocarpine, chamomile (akkal-kadha), echinacea, coleus, gentian, zanthoxylum, hay, ginger, club grass, cardomom, monosodium glutamate, and mixtures thereof.

Mucoadhesive (mucoadhesive) or bioadhesive may also be used in the present invention. Such binders include, but are not limited to, polyoxyethylene homopolymers, Carbopol , Plasdone , CMC, HEC, Klucel , hydroxypropyl methylcellulose, Gantrez , polyacrylates, and mixtures thereof. These and other suitable and preferred mucoadhesives or bioadhesives are described in detail in U.S. patent 4,900,522; 5,284,659, respectively; 5,458,879, respectively; 5,989,535, respectively; 6,177,096; 6,200,604, respectively; 6,207,180, respectively; 6,210,705, respectively; 6,213,126, respectively; each of which is incorporated herein by reference in its entirety.

Water or hydroalcoholic mixtures may also be present in the microcapsules of the present invention. The water content is from about 0.1% to about 15%, preferably from about 1% to about 10%, more preferably from about 1% to about 7% of the microcapsules of the invention. These amounts of water include added free water plus water introduced with other materials such as sorbitol. The water should preferably be deionized, distilled, and free of organic impurities, bacteria, and substantially free of metal ions.

Preparation method

Microcapsules of the present invention can be prepared using a variety of conventional techniques. One method is described in the examples below.

Industrial applicability

The microcapsules of the present invention are used by placing the capsule in the mouth and allowing it to remain for a period of time sufficient to achieve the desired effect.

The following examples further describe and demonstrate preferred embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention. Many variations thereof are possible without departing from the spirit and scope of the invention.

Examples

The following compositions/capsules are representative of the present invention.

	Example 1	Example 2	Example 3	Example 4
					Composition (I)	％w/w	％w/w	％w/w	％w/w
Gelatin	12.570	12.320	15.070	5.250
					Sorbitol	2.060	2.050	-----	-----
Acesulfame potassium	0.1690	0.1920	-----	-----
					Sucralose	0.3960	0.4490	0.641	0.700
Glycerol	-----	-----	2.04	2.04
					Water (W)	0.485	0.550	0.600	0.575
Flavouring agent	1-10	1-10	1-10	1-10
					Thymol	0.833	0.821	1.250	1.642
Salicylic acid methyl ester	0.712	0.700	1.068	1.400
					Eucalyptol	0.781	0.770	1.172	1.540
Menthol	12.439	12.261	16.159	21.522
					Neobee M-5	Adding to 100 percent	Adding to 100 percent	Adding to 100 percent	Adding to 100 percent

The above compositions are prepared by mixing the core ingredients in one container and the shell ingredients in another container. The shell material is heated to provide a fluid medium. The core and shell materials are then pumped separately into two or three fluid nozzles immersed in an organic carrier medium. The formed capsules are allowed to cool and harden. And then denatured and separated for further processing.

In the above compositions, any of a wide variety of other shell materials, mouth-control agents, sweeteners, and other ingredients may be used in place of or in combination with the ingredients listed above.

Claims (9)

1. A microcapsule composition comprising a shell material and a core material, wherein the microcapsule comprises:

a.) an essential oil mixture comprising thymol, eucalyptol, methyl salicylate and menthol; and

b.) chlorodeoxysucrose derivatives having the formula:

wherein R is¹Represents a hydroxyl group or a chlorine atom; r²And R³Respectively represents a hydroxyl group and a hydrogen atom, a chlorine atom and a hydrogen atom, or a hydrogen atom and a chlorine atom, wherein the 4-position is in the D-configuration; r⁴Represents a hydroxyl group; or, if R is¹、R²、R³And R⁵In which at least two represent chlorine atoms, then R⁴Represents a hydroxyl group or a chlorine atom; and R is⁵Represents a hydroxyl group or a chlorine atom; with the following conditions: r¹、R²、R³And R⁵At least one of them represents a chlorine atom,

and wherein the shell material is of the fast dissolving type.

2. The microcapsule of claim 1, wherein the shell material is selected from the group consisting of polyvinyl alcohol, gelatin, pullulan, wax, gum, and candy.

3. A microcapsule according to any preceding claim wherein the microcapsule is spherical or ellipsoidal in shape.

4. The microcapsule according to any of the preceding claims, wherein the microcapsule has a diameter of from about 2mm to about 9mm and a shell wall thickness of from 30 μm to 2 mm.

5. A microcapsule according to any preceding claim wherein the microcapsule further comprises a humectant.

6. A microcapsule according to any preceding claim wherein the microcapsule dissolves in 60 seconds.

7. A microcapsule according to any preceding claim wherein the chlorodeoxysucrose derivative is sucralose.

8. A microcapsule composition comprising a shell material and a core material, wherein the microcapsule comprises:

a.) an essential oil mixture comprising thymol, eucalyptol, methyl salicylate and menthol; and

b.) chlorodeoxysucrose derivatives having the formula:

wherein R is¹Represents a hydroxyl group or a chlorine atom; r²And R³Respectively represents a hydroxyl group and a hydrogen atom, a chlorine atom and a hydrogen atom, or a hydrogen atom and a chlorine atom, wherein the 4-position is in the D-configuration; r⁴Represents a hydroxyl group; or, if R is¹、R²、R³And R⁵In which at least two represent chlorine atoms, then R⁴Represents a hydroxyl group or a chlorine atom; and R is⁵Represents a hydroxyl group or a chlorine atom; with the following conditions: r¹、R²、R³And R⁵At least one of them represents a chlorine atom; and

c.) optionally up to 15% of water

With the following conditions: when water is added, it evaporates from the microcapsules during processing to maintain the core material as a single phase.

9. A microcapsule composition comprising a shell material and a core material, wherein the microcapsule comprises:

a.) an essential oil mixture comprising thymol, eucalyptol, methyl salicylate and menthol; and

b.) chlorodeoxysucrose derivatives having the formula:

wherein R is¹Represents a hydroxyl group or a chlorine atom; r²And R³Respectively represents a hydroxyl group and a hydrogen atom, a chlorine atom and a hydrogen atom, or a hydrogen atom and a chlorine atom, wherein the 4-position is in the D-configuration; r⁴Represents a hydroxyl group; or, if R is¹、R²、R³And R⁵In which at least two represent chlorine atoms, then R⁴Represents a hydroxyl group or a chlorine atom; and R is⁵Represents a hydroxyl group or a chlorine atom; with the following conditions: r¹、R²、R³And R⁵Wherein at least one represents a chlorine atom(ii) a And

c.) acetyl-L-,

wherein the ratio of the chlorodeoxysucrose derivative to the acesulfame is 1: 1-9: 1.